Is it time to give up the search for an Aids vaccine?
By Steve Connor and Chris Green (Independent UK) 24 April 2008: After 25 years and billions of pounds, leading scientists are now forced to ask this question
Most scientists involved in Aids research believe that a vaccine
against HIV is further away than ever and some have admitted that
effective immunisation against the virus may never be possible,
according to an unprecedented poll conducted by The Independent.
A mood of deep pessimism has spread among the international community
of Aids scientists after the failure of a trial of a promising vaccine
at the end of last year. It just was the latest in a series of setbacks
in the 25-year struggle to develop an HIV vaccine.
The Independent's survey of more than 35 leading Aids scientists in
Britain and the United States found that just two were now more
optimistic about the prospects for an HIV vaccine than they were a year
ago; only four said they were more optimistic now than they were five
years ago.
Nearly two thirds believed that an HIV vaccine will not be developed
within the next 10 years and some of them said that it may take at
least 20 more years of research before a vaccine can be used to protect
people either from infection or the onset of Aids.
A substantial minority of the scientists admitted that an HIV vaccine
may never be developed, and even those who believe that one could
appear within the next 10 years added caveats saying that such a
vaccine would be unlikely to work as a truly effective prophylactic
against infection by the virus.
One of the major conclusions to emerge from the failed clinical trial
of the most promising prototype vaccine, manufactured by the drug
company Merck, was that an important animal model used for more than a
decade, testing HIV vaccines on monkeys before they are used on humans,
does not in fact work.
This has meant that prototype HIV vaccines which appear to work well
when tested on monkeys infected with an artificial virus do not work
when tested on human volunteers at risk of HIV – a finding that will be
exploited by anti-vivisectionist campaigners opposed to vaccine
experiments on primates.
Anthony Fauci, the director of the US National Institute of Allergy and
Infectious Diseases (NIAID), near Washington, told The Independent that
the animal model – which uses genetically engineered simian and human
immunodeficiency viruses in a combination, known as SHIV – failed to
predict what will happen when a prototype vaccine is moved from
laboratory monkeys to people. "We've learnt a few important things
[from the clinical trial]. We've learnt that one of the animal models,
the SHIV model, really doesn't predict very well at all," he
said.
"At least we now know that you can get a situation where it looks like
you are protecting against SHIV and you're not protecting at all in the
human model – that's important," he said.
The NIAID spends about $500m (£250m) on HIV vaccine research each year
and despite calls from some Aids pressure groups for funds to be
diverted to other forms of Aids prevention, Dr Fauci said this was not
the time to stop vaccine research. "I don't think you should say that
this is the point where we're going to give up on developing a vaccine.
I think you continue given that there are so many unanswered questions
to answer," he said. "There is an impression given by some that if you
do vaccine research you are neglecting other areas of prevention.
That's not the case. We should and we are doing them
simultaneously."
More than 80 per cent of the scientists who took part in our survey
agreed that it was now important to change the direction of HIV vaccine
research, given the failure of the Merck clinical trial, which was
cancelled when it emerged that the vaccine may have actually increased
the chances of people developing Aids.
Robert Gallo, a prominent Aids researcher in the US who is credited
with co-discovering the virus in the early 1980s, likened the vaccine's
failure to the Challenger disaster, which forced Nasa to ground the
space shuttle fleet for years.
At the end of last month, Dr Fauci convened a high-level summit of
leading HIV specialists at a hotel in Bethesda, Maryland, to discuss
the future direction of research. A group of 14 prominent Aids
specialists had already written to
Dr Fauci suggesting that his institute had "lost its way" in terms of
an HIV vaccine.
He said that one outcome of the meeting was a refocusing of the vaccine
effort away from expensive clinical trials towards more fundamental
research to understand the basic biology of the virus and its effects
on the human immune system.
"We'll be turning the knob more towards answering some fundamental
questions rather than going into big clinical trials," Dr Fauci said.
"I'm certainly disappointed that we're not further ahead in the
development of a vaccine but I don't say that this year I'm more
discouraged than I was last year. I always knew from the beginning that
it would be a very difficult task given what we know about this very
elusive virus."
About 33 million people in the world are infected with HIV and some 26
million have died of Aids since the pandemic began.
The majority of scientists who responded to The Independent's survey
said that a vaccine would be the most effective way of preventing the
spread of the virus given the failure of many education
programmes.
Winnie Sseruma, 46: 'For me, the key has been not to give up'
Ms Sseruma says she believes abandoning research for a vaccine would
mean a loss of hope for millions of people. "When I was diagnosed,
nearly 20 years ago, it was when the first drugs had come on the
market. A lot of people had said before then that there was no hope and
that all efforts should be put into prevention. But look where we are
now.
We cannot lose hope; we need to invest in a vaccine."
She says this latest failure needs to be seen as the first hurdle, not
a signal to give up. "Yes, the scientists have not been very successful
in their quest for a vaccine, but you can learn a lot from failures.
Now they have realised they cannot use the normal routes used to
develope simpler vaccines."
Ms Sseruma lives in London, but was born in Uganda and says that the
current climate of pessimism for the vaccine is not dissimilar to the
initial doubts over the likelihood of treating HIV in Africa.
"I remember when treatment started being available in the West and
people were saying it would be impossible to send it to Africa. But
look what's happened. We should always do whatever is humanly possible
to fight Aids. It's been a long journey, but for me, the key has been
not to give up, and the scientists need to have the same
attitude."
'Philippe B', 42: 'People are getting resistant to drugs'
"Philippe", who wishes to remain anonymous, discovered he was HIV
positive 11 years ago. The 42-year-old believes the search for the
vaccination should no longer be a priority, but that it should not stop
altogether.
"Unfortunately what's happening now is that people are getting more
resistant to drug treatment, and more money needs to be put into
finding more drugs for treatment," he said.
For people like Philippe, the fear of building an immunity to drugs and
running out of options is a real one. He believes that as long as
scientists are still pessimistic about the chances of successfully
finding a vaccine, money needs to be invested in continuing to fund
research into treatment.
"I've already become resistant to five combination treatments over the
last ten years, and if I was on the last one available I'd be very
afraid. HIV is not a death sentence in the way it once was, but we do
need to fund further research into the drugs that treat it."
Nevertheless, Philippe thinks it is not yet time to abandon all
research into a vaccine. "In my lifetime I don't think we'll have a
vaccine, but there's no reason we should believe it isn't possible," he
said. "But we should now be spending more on other ways of dealing with
the disease."

